Moreover, Biogen’s valuation appears to be fairly priced at current levels, as indicated by a Discounted Cash Flow analysis projecting revenues through 2033. While the company has potential ...

Biogen Inc. (NASDAQ:BIIB), a leader in biotechnology, announced the appointment of Sean Godbout as Vice President, Chief Accounting Officer & Global Corporate Controller, effective March 1, 2025 ...

Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company's challenges in establishing its presence in the market for Alzheimer ...

Investing.com -- Piper Sandler downgraded Biogen Inc (NASDAQ:BIIB) from “overweight” to “neutral,” given a challenging transition period for the biotech firm. The brokerage hacked the ...

The stock’s performance has been below most large drugmakers’ performance. Biogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS ...